Carbamazepine (Epilepsy)

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10075
R36693
Coste (Carbamazepine), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick Adjustment: No 1.34 [0.75;2.37] C 14/176   128/2,108 142 176
ref
S5925
R15072
Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 Low birth weight (< 2500g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.38 [0.58;3.27] C
excluded (control group)
51/1,077   6/173 57 1,077
ref
S5909
R14887
Artama (Carbamazepine) (Controls unexposed, disease free), 2013 Low birth weight (< 2500g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.63 [1.23;2.17]
excluded (control group)
51/1,077   21,546/719,509 21,597 1,077
ref
S5917
R14983
Artama (Carbamazepine) (Controls unexposed, sick), 2013 Low birth weight (< 2500g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.31 [0.89;1.92] 51/1,077   65/1,793 116 1,077
ref
S6356
R21028
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 Low birth weight (< 2500 grams) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.30 [0.38;4.46] C
excluded (control group)
5/67   6/103 11 67
ref
S6354
R17338
Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 Low birth weight (< 2500 grams) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: Yes 1.80 [0.70;4.40]
excluded (control group)
5/67   5,024/106,899 5,029 67
ref
S6355
R17334
Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 Low birth weight (< 2500 grams) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 1.86 [0.66;5.27] C 5/67   16/386 21 67
ref
S7181
R20253
Kini (Carbamazepine) (Controls unexposed, sick), 2006 Birth weight <2500 g during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 0.27 [0.07;1.00] C 3/94   11/101 14 94
ref
Total 4 studies 1.16 [0.71;1.92] 293 1,414
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Carbamazepine), 2020Coste, 2020 1 1.34[0.75; 2.37]14217631%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Artama (Carbamazepine) (Controls unexposed, sick), 2013Artama, 2013 2 1.31[0.89; 1.92]1161,07741%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013Veiby, 2013 3 1.86[0.66; 5.27]216716%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: moderateROB mesure: moderateROB reporting: moderate Kini (Carbamazepine) (Controls unexposed, sick), 2006Kini, 2006 4 0.27[0.07; 1.00]149411%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: unclearROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 50% 1.16[0.71; 1.92]2931,4140.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick) ; 4: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.16[0.71; 1.92]2931,41450%NACoste (Carbamazepine), 2020 Artama (Carbamazepine) (Controls unexposed, sick), 2013 Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 Kini (Carbamazepine) (Controls unexposed, sick), 2006 4 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.00[0.42; 2.39]1511,23866%NAArtama (Carbamazepine) (Controls unexposed, sick), 2013 Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 Kini (Carbamazepine) (Controls unexposed, sick), 2006 3 exposed to other treatment, sickexposed to other treatment, sick 1.34[0.75; 2.37]142176 -NACoste (Carbamazepine), 2020 1 Tags Adjustment   - No  - No 0.99[0.39; 2.51]17733766%NACoste (Carbamazepine), 2020 Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 Kini (Carbamazepine) (Controls unexposed, sick), 2006 3   - Yes  - Yes 1.31[0.89; 1.92]1161,077 -NAArtama (Carbamazepine) (Controls unexposed, sick), 2013 1 All studiesAll studies 1.16[0.71; 1.92]2931,41450%NACoste (Carbamazepine), 2020 Artama (Carbamazepine) (Controls unexposed, sick), 2013 Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 Kini (Carbamazepine) (Controls unexposed, sick), 2006 40.15.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.61.70.8020.000Coste (Carbamazepine), 2020Artama (Carbamazepine) (Controls unexposed, sick), 2013Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013Kini (Carbamazepine) (Controls unexposed, sick), 2006

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 5925, 5909, 6356, 6354

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.64[1.25; 2.16]26,6261,1440%NAArtama (Carbamazepine) (Controls unexposed, disease free), 2013 Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 2 unexposed, sick controlsunexposed, sick controls 1.00[0.42; 2.39]1511,23866%NAArtama (Carbamazepine) (Controls unexposed, sick), 2013 Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 Kini (Carbamazepine) (Controls unexposed, sick), 2006 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.34[0.86; 2.10]2101,3200%NACoste (Carbamazepine), 2020 Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 30.510.01.0